Cannabis-based treatment will be offered to dementia patients
Cannabis will be used to treat symptoms of dementia in the first major UK trial to test its use, scientists have announced.
Pensioners with symptoms of Alzheimer’s disease will be recruited to see how cannabis-based treatment compares with a dummy drug.
Scientists are testing whether Sativex - a Peppermint-flavoured mouth spray containing cannabinoids - could be used to reduce symptoms of agitation or aggression.
Around half of the 850,000 dementia sufferers in the UK experience such symptoms, as well as memory problems and confusion.
The drug is already prescribed to some patients with multiple sclerosis to relieve muscle stiffness and spasms.
Alzheimer’s Research UK is committing £300,000 funding to the Kings College London trial, involving elderly patients living in care homes.
The study team will recruit 60 volunteers with Alzheimer’s disease between 55 and 90 years old who are living in care homes and have symptoms of agitation or aggression.
Volunteers will take the medication for four weeks, with results compared with those given a placebo drug.
Lead researcher Prof Dag Aarsland said: “While people most often associate Alzheimer’s disease with memory problems, this is just one aspect of a complex condition that can affect people in different ways.
“Many people with Alzheimer’s can become agitated or aggressive, and this can pose difficulties for the person with the condition and those closest to them,” the psychiatrist said.
“Current treatments for behavioural and psychiatric symptoms of dementia are very limited, and we desperately need to develop alternatives. Doctors sometimes prescribe anti-psychotic medications, and while these drugs can have important benefits, these need to be weighed against the risk of very serious side effects.
Although Sativex is licensed for treatment of some MS symptoms, it is not currently licensed in the UK for any other indication, including treatment of the symptoms of dementia.
The drug is a peppermint-flavoured mouth spray that contains a 1:1 ratio of two key cannabinoids found in the cannabis plant – delta-9-tetrahydrocannabinol (THC) and cannabidiol (CBD).
If successful, the trial will be followed by a much larger study.
Dr David Reynolds, chief scientific officer of Alzheimer’s Research UK, warned against the use of cannabis in an uncontrolled setting, saying the drug carries risks - including to short-term memory, and anxiety.
He said: “With no new dementia treatments in over 15 years, it is vital that we test a wide range of approaches to find effective ways to help people living with the condition.
“While a major focus for dementia research is to develop drugs that slow or stop the progression of the physical diseases that cause dementia, what really matters is that a medicine benefits people’s day-to-day lives.
“This is a rigorous clinical trial of a medication that has been carefully prepared, and which will be tested in circumstances where the health and wellbeing of participants can be closely monitored. There is no good evidence that using cannabis in an uncontrolled setting could benefit people living with dementia, and we know that the drug can involve risks including short-term memory and thinking problems, coordination difficulties and anxiety.”
